Market Place
News Type
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
X
Details:
Elunate (Fruquintinib) is a highly selective and potent oral inhibitor of VEGFR-1, -2 and -3. VEGFR inhibitors play a pivotal role in blocking tumor angiogenesis.
Lead Product(s): Fruquintinib
Therapeutic Area: Oncology Product Name: Elunate
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2022
Details:
Elunate (fruquintinib) is a highly selective and potent oral inhibitor of VEGFR-1, -2 and -3. VEGFR inhibitors play a pivotal role in blocking tumor angiogenesis.
Lead Product(s): Fruquintinib
Therapeutic Area: Oncology Product Name: Elunate
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 23, 2022
Details:
Fruquintinib is a highly selective and potent oral inhibitor of VEGFR-1, -2 and -3. VEGFR inhibitors play a pivotal role in blocking tumor angiogenesis. Fruquintinib was designed to improve kinase selectivity to minimize off-target toxicities, improve tolerability.
Lead Product(s): Fruquintinib
Therapeutic Area: Oncology Product Name: Elunate
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2022
Details:
TAZVERIK® (tazemetostat) is a methyltransferase inhibitor indicated in the United States for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.
Lead Product(s): Tazemetostat
Therapeutic Area: Oncology Product Name: Tazverik
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2022
Details:
TAZVERIK (tazemetostat), is a methyltransferase inhibitor of EZH21 is approved by the FDA for the treatment of certain patients with ES and certain patients with FL.
Lead Product(s): Tazemetostat
Therapeutic Area: Oncology Product Name: Tazverik
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Epizyme
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2022
Details:
Fruquintinib is a highly selective and potent oral inhibitor of VEGFR-1, -2 and -3. VEGFR inhibitors play a pivotal role in blocking tumor angiogenesis. ELUNATE® will become the first homegrown innovative oncology drug to be marketed in Macau based on its approval by the NMPA.
Lead Product(s): Fruquintinib
Therapeutic Area: Oncology Product Name: Elunate
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2022
Details:
Elunate (Fruquintinib), an investigational product for the treatment of patients with metastatic colorectal cancer met primary endpoint of the study, overall survival achieved.
Lead Product(s): Fruquintinib
Therapeutic Area: Oncology Product Name: Elunate
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 09, 2021
Details:
As per the agreement, SULANDA® will enter the NRDL, along with the renewal of ELUNATE®. The NRDL has made it possible for novel therapies to gain wide reach across the country for diseases with large patient populations.
Lead Product(s): Fruquintinib
Therapeutic Area: Oncology Product Name: Elunate
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: National Healthcare Security Administration
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 03, 2021
Details:
ORPATHYS® is an oral, potent, and highly selective MET TK inhibitor that has shown clinical activity in advanced solid tumors. It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations or gene amplification.
Lead Product(s): Savolitinib
Therapeutic Area: Oncology Product Name: Orpathys
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: $140.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration July 13, 2021
Details:
Fruquintinib is a highly selective and potent oral inhibitor of vascular endothelial growth factor receptor (“VEGFR”) 1/2/3. Fruquintinib was approved by the China National Medical Products Administration (“NMPA”) in September 2018 under the brand name Elunate®.
Lead Product(s): Fruquintinib
Therapeutic Area: Oncology Product Name: Elunate
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $104.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 18, 2021
